AVT06, a proposed biosimilar to aflibercept (Eylea; Regeneron Pharmaceuticals), demonstrated comparable efficacy, safety, and immunogenicity to the reference product in people with neovascular age-related macular degeneration (nAMD), according to a…
Proposed Aflibercept Biosimilar Shows Comparable Safety, Efficacy in Phase 3 AMD Trial
